New drug shows promise for Hard-to-Treat lymphoma
NCT ID NCT06485219
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study tests a new drug called purinostat mesylate in 50 people with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The main goal is to see if the drug can shrink tumors. Researchers will also check for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA (CTCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, 200000, China
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.